KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Charles River Laboratories International (CRL) Cash & Equivalents (2016 - 2025)

Historic Cash & Equivalents for Charles River Laboratories International (CRL) over the last 17 years, with Q3 2025 value amounting to $207.1 million.

  • Charles River Laboratories International's Cash & Equivalents fell 146.26% to $207.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $207.1 million, marking a year-over-year decrease of 146.26%. This contributed to the annual value of $194.6 million for FY2024, which is 2968.7% down from last year.
  • Latest data reveals that Charles River Laboratories International reported Cash & Equivalents of $207.1 million as of Q3 2025, which was down 146.26% from $182.8 million recorded in Q2 2025.
  • Charles River Laboratories International's Cash & Equivalents' 5-year high stood at $465.4 million during Q1 2021, with a 5-year trough of $157.2 million in Q3 2023.
  • In the last 5 years, Charles River Laboratories International's Cash & Equivalents had a median value of $210.2 million in 2024 and averaged $230.4 million.
  • Its Cash & Equivalents has fluctuated over the past 5 years, first crashed by 4803.11% in 2022, then soared by 6223.22% in 2024.
  • Quarter analysis of 5 years shows Charles River Laboratories International's Cash & Equivalents stood at $241.2 million in 2021, then fell by 3.03% to $233.9 million in 2022, then rose by 18.32% to $276.8 million in 2023, then fell by 29.69% to $194.6 million in 2024, then grew by 6.42% to $207.1 million in 2025.
  • Its Cash & Equivalents was $207.1 million in Q3 2025, compared to $182.8 million in Q2 2025 and $229.4 million in Q1 2025.